PDCD1 and cancer: The benefits of the combination treatment of anti-angiogenesis inhibitors such as bevacizumab, axitinib, and lenvatinib and anti-PD-1/PD-L1 antibodies have been reported in pre-clinical and even in clinical settings, and some combination therapies have already been approved as cancer treatments19.